Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLERO-3: everolimus + trastuzumab + vinorelbine versus placebo + trastuzumab + vinorelbine in trastuzumab-resistant HER2-positive advanced breast cancer
2008-008697-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Everolimus + trastuzumab + vinorelbine with Placebo + trastuzumab + vinorelbine (2 arms). Primary endpoint: Progression-free survival. Started Aug 2009; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-008697-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008697-31.